Australian Clinical Labs Ltd (ASX:ACL)

Full Year 2026 Australian Clinical Labs Limited Earnings Presentation Transcript

Aug 16, 2026 / 01:00 AM GMT

Release Date Price: A$2.7 (+14.89%)

Transcript

Key Points

Positve

Underlying EBIT margin improved to 9.4%, above the top end of guidance, with second-half margin at 11%.
Underlying NPAT grew 4.3% and EPS rose 8.5% despite a challenging market.
Returned $47 million to shareholders via dividends and buybacks, with a 5.5% yield and 69% payout ratio.
Return on invested capital improved to 25.2%, above the 75th percentile of the ASX 300.
Strong cash conversion of 119.2% of EBITDA into operating cash flow, with free cash flow of $64.7 million.
Operational efficiencies delivered: 10.4% increase in lab panels per FTE and 13% logistics efficiency gain, reducing kilometres by nearly 1 million.
Non-Medicare revenue now ~20% of total, with commercial contract revenue up 17% and genetics/non-MBS up over 7%.
Single national laboratory information system (LIS) provides a structural competitive advantage, enabling rapid deployment of billing and automation initiatives.
FY27 guidance reflects margin stability despite headwinds, with a strong pipeline of new profitable collection centres and growth initiatives.
New CEO Greg Horan brings extensive healthcare experience and a focus on disciplined execution and value creation.

Negative

Revenue declined to $736 million, down on the prior corresponding period due to low market volumes and fee cuts.
Absorbed approximately $14 million in net Medicare fee cuts (vitamin B12 and urine testing) and faced sluggish GP consultation market.
Incurred $1.8 million in gender undervaluation costs and faced annual wage increases of 3.5% plus superannuation rise.
Free cash flow decreased to $64.7 million from the prior year, partly due to lower revenue.
Statutory NPAT was $24 million, significantly below underlying NPAT due to one-off items including a $6.2 million AIC settlement and $4.2 million prepayment write-back.
FY27 guidance includes continued wage pressure, with an estimated $7 million impact from gender undervaluation for collectors and health professionals.
Market volumes remain below long-term trends, with GP attendances and pathology episodes still sluggish.
Some public hospital work was insourced by the state, reducing revenue.
The company exited unprofitable collection centres and contracts, leading to a short-term revenue decrease.
Net debt increased to $37.4 million, though still conservative at 0.5 times EBITDA.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ACL.AX - Australian Clinical Labs Limited
Full Year 2026 Australian Clinical Labs Limited Earnings Presentation
Aug 17, 2026 / 01:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning everyone.

On behalf of ACL, I'd like to start by acknowledging the traditional custodians of the land on which we meet today.

Today I'm joining you from Brisbane on the lands of the Turrbal, Yuggera and Jagera peoples.

We acknowledge the traditional custodians of country throughout Australia and the places from which our participants join us on this webinar.

And their connections to land, sea and community. We pay our respects to their elders, past and present, and extend that respect to Aboriginal and Torres Strait Islander peoples here today.

Welcome to the Investor webinar for Australian Clinical Labs, full year financial results.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by FactSet. Analyst estimates data is sourced from both Refinitiv and FactSet, with priority given to Refinitiv data. Data is updated daily.